The Quantellect read.As of Nov 19, 2026, 5 active firms cover Vanda Pharmaceuticals Inc: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $7.50 to $20.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $13.50 sits 259% above the current $3.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.50
+258.6% upside
Average target across 5 active firms as of Nov 19, 2026 vs $3.77 current
Highest Target$20.00
Average Target$13.50
Lowest Target$7.50
Detailed analyst forecasts for VNDA
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate VNDA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VNDA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.32 – $-0.16 · 3 analysts · -70% YoY
Next period, 3 analysts expect Vanda Pharmaceuticals Inc to earn $-0.25 a share (range $-0.32 – $-0.16), versus $-0.82 a year earlier. Full-year consensus is $-2.52, growing to $-0.74 the year after.
REVENUE · NEXT QUARTER
$72.4M
Range $69.2M – $76.0M · 3 analysts · +40% YoY
Revenue is expected to reach $72.4M (range $69.2M – $76.0M), +40.0% year-over-year. Full-year consensus is $242.1M, rising to $316.3M next year.
Top analysts covering Vanda Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VNDA.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$20.00+431.2% to target
Overall win rate
36%
+ Follow
#2
ME
Madison El-Saadi
B. Riley Securities
Buy
$12.00+218.7% to target
Coverage
—
+ Follow
#3
LS
Les Sulewski
Truist Securities
Buy
$18.00+378.1% to target
Coverage
—
+ Follow
#4
OB
Olivia Brayer
Cantor Fitzgerald
Buy
$11.00+192.2% to target
Coverage
—
+ Follow
#5
Andrew Tsai
Jefferies
Neutral
$7.50+99.2% to target
Coverage
—
+ Follow
VNDA stock forecast FAQ
What is VNDA's average 12-month price target?+
The 5 active firms with a live target average $13.50 for Vanda Pharmaceuticals Inc over the next 12 months, ranging from a $20.00 high to a $7.50 low, as of Nov 19, 2026.
Is VNDA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VNDA?+
The Street-high target is $20.00 (HC Wainwright & Co.), and the Street-low is $7.50 (Jefferies). The average of all 5 active-firm targets is $13.50.
How many active Wall Street firms cover VNDA?+
5 active firms have a recognized rating on Vanda Pharmaceuticals Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VNDA?+
Among analysts who currently cover VNDA, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #423). Their current call is Buy with a $20.00 target.
What is Vanda Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.32 – $-0.16) across 3 analysts. Full-year EPS is projected at $-2.52, rising to $-0.74 the following year.
How much revenue is Vanda Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $72.4M (range $69.2M – $76.0M). Full-year revenue is projected at $242.1M, growing to $316.3M next year.
Have analysts been upgrading or downgrading VNDA lately?+
As of Nov 19, 2026, 4 of 5 active firms rate VNDA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VNDA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.